3 February 2012 - US medical technology company Stryker Corporation unveiled on 2 February 2012 positive results of the TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke).

TREVO was one of the first prospective, multicentre clinical studies of clot-removing stent retriever technology. It enrolled sixty patients in seven stroke centres in Europe.

The trial was aimed at evaluating the ability of the Trevo System to remove blood clots that cause strokes and to restore blood flow to the brain.

The data showed high revascularisation rates of 91.7% of patients, with 46% achieving a good outcome in just seven days and 55% achieving good outcome at 90 days.